Business, energy, technology, markets and global industry news from Business News Today

Skip to content

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

lumipodlin

PharmaDeviceNews lumipodlin

Abbisko Therapeutics and AstraZeneca are testing oral PD-L1 inhibitor lumipodlin with Tagrisso in EGFR-mutated non-small cell lung cancer, putting safety, pneumonitis risk and treatment durability under close scrutiny. Representative image.

Pharma & Biotech

AstraZeneca adds Abbisko’s lumipodlin to expanding Tagrisso combination strategy

by Pallavi Madhiraju
July 2, 2026
0 Comments

Discover why Abbisko and AstraZeneca are testing oral PD-L1 inhibitor lumipodlin with Tagrisso in EGFR-mutated lung cancer.

Read More

Latest news and features

Ionis wins first FDA approval for Alexander disease. Can Zanvastro make an ultra-rare launch work?
AstraZeneca’s Etcamah wins FDA approval after cutting progression risk 56%. What changes for breast cancer care?
FDA allows trial of controlled low-dose lenalidomide with Pfizer’s Elrexfio in multiple myeloma
CorrectSequence base editing keeps sickle cell patient crisis-free for 18 months
Rznomics improves 8 kb circular RNA production as manufacturing race for next-gen RNA drugs accelerates
636-patient angiogenesis review finds no cancer signal as Isomab prepares ISM-001 for first human study
Teleflex Dynetic-35 achieves 100% procedural success in radial iliac stenting feasibility study
Aptar and Aceso move inhaled ACT-101 RNA therapy toward clinical development in cystic fibrosis
Insilico rentosertib makes six proteomic aging clocks trend younger in IPF trial
Co-Diagnostics deploys Vector Smart mosquito PCR surveillance at overseas U.S. Air Force base
Sonorous BosSTENT study tests brain-vein stenting for debilitating pulsatile tinnitus
Keytruda generated $31.6bn last year. Cipla and Qilu are positioning a biosimilar for the U.S. market

POPULAR NEWS

Representative image of a clinician reviewing skeletal imaging, illustrating Mirum Pharmaceuticals and Incyte’s zilurgisertib Phase 2 progress in fibrodysplasia ossificans progressiva and the rare disease treatment questions facing regulators.

Pharma & Biotech

Why Mirum Pharmaceuticals and Incyte’s zilurgisertib data could reset expectations in FOP treatment

June 15, 2026

Niagen Bioscience’s NB4168 has secured U.S. FDA Rare Pediatric Disease and European orphan designations as the company advances the experimental ataxia telangiectasia therapy toward human trials. Representative image.

Pharma & Biotech

Niagen wins twin rare-disease designations, but can NB4168 turn nicotinamide riboside evidence into a medicine?

July 14, 2026

Representative image of biopharma laboratory research. Gilead Sciences and Merck’s latest Phase 3 updates highlight the promise of once-weekly HIV treatment with islatravir and lenacapavir, while raising fresh questions over Trodelvy’s lung cancer expansion strategy.

Pharma & Biotech

Gilead and Merck pipeline update reveals promise in HIV and pressure in oncology

June 9, 2026

Latest business and industry news

Ceigall India moves beyond EPC with a 35-year Gujarat transmission revenue stream
International Frontier (TSXV: IFR) signs Mexico gas deals ahead of C$38m RTO
Ingenia (ASX: INA) rejects A$1.94bn Warburg bid as shares jump 16%
Philippines warns China could exploit Trump’s cuts to U.S.–South Korea military exercises
Green Canada Uranium cleared for TSXV debut after C$2.9m financing and RTO

TAGS

clinical trials Eli Lilly and Company European Medicines Agency FDA FDA approval immuno-oncology immunotherapy Inc. Johnson & Johnson medical devices oncology precision oncology U.S. Food and Drug Administration United States Food and Drug Administration US Food and Drug Administration

About PharmaDeviceNews
Disclaimer
Editorial Policy
Privacy Policy
Contact Us

© 2026 PharmaDeviceNews.com. All rights reserved.